(NVO) Novo Nordisk A/S BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NVO) Novo Nordisk A/S Complete Analysis Pack
Visual. Strategic. Downloadable.
This Novo Nordisk A/S BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Wegovy 2.4 mg obesity 2021
Wegovy 2.4 mg is Novo Nordisk A/S’s flagship obesity brand, and 2024 sales reached DKK 58.2bn, showing how central it is to growth. Demand stays strong in a market that is still expanding fast, so supply, access, and promotion remain key to defend share. If growth normalizes, the brand can shift from a Star to a Cash Cow.
Ozempic 0.5 to 2 mg T2D 2017
Ozempic is still a Star in Novo Nordisk A/S's BCG mix: 2024 sales reached about DKK 120.5bn, up 26% year on year, and the brand keeps leading the GLP-1 and type 2 diabetes market. Broad prescriber use and strong real-world awareness support its scale, while Novo Nordisk kept 2025 sales growth guidance at 16% to 24%. That makes Ozempic a core revenue engine as the market keeps expanding.
Rybelsus 7 to 14 mg oral GLP-1 2019
Rybelsus, launched in 2019, is the first oral GLP-1 tablet and a clear Star in Novo Nordisk A/S’s BCG matrix. Its 7 mg to 14 mg dosing broadens semaglutide beyond injections, taps a convenience-led diabetes market, and helps support share gains in a class that keeps growing. It still needs strong commercial push to keep adoption rising.
Semaglutide CV risk reduction 2024
In 2024, semaglutide’s cardiovascular label broadened the market beyond glucose control and reinforced its Star status for Novo Nordisk A/S. The SELECT trial showed a 20% cut in major adverse CV events, which strengthened payer interest and supported premium pricing.
This added clinical value lifted demand for Wegovy and Ozempic, helping the franchise compete better with rival incretin drugs like Eli Lilly’s tirzepatide. Novo Nordisk A/S reported 2024 revenue of DKK 290.4bn, with obesity care and diabetes growth still driving the mix.
- 20% MACE reduction in SELECT
- Expanded use beyond glucose control
- Stronger payer and brand pull
- Supports Star territory
Diabetes and Obesity Care growth engine 2025
Diabetes and Obesity Care is Novo Nordisk A/S’s main growth engine, led by Wegovy and Ozempic. In 2025, the unit kept growing fast as obesity, diabetes, and cardiovascular demand stayed strong, but it still needed heavy investment in supply and R&D. Its share position remains one of Novo Nordisk A/S’s strongest.
- Core growth platform in 2025
- Driven by obesity and diabetes demand
- Needs high capex and R&D spend
- Strongest market-share position
Wegovy and Ozempic Keep Novo Nordisk’s Growth Engine Running
Wegovy, Ozempic, and Rybelsus stay Stars in Novo Nordisk A/S’s BCG mix because demand is still rising fast and the GLP-1 market keeps expanding. Wegovy sales hit DKK 58.2bn in 2024, and Ozempic reached about DKK 120.5bn, up 26% year on year.
| Star | 2024 sales | Why it matters |
|---|---|---|
| Wegovy | DKK 58.2bn | Obesity growth |
| Ozempic | DKK 120.5bn | Diabetes scale |
| Rybelsus | N/A | Oral GLP-1 reach |
What is included in the product
Detailed Word Document
Novo Nordisk A/S BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide investment and divestment decisions.
Editable Excel File
One-page Novo Nordisk BCG Matrix that simplifies portfolio pain points for fast, clear strategic review
Reference Sources
Provides a credible source trail for Novo Nordisk A/S, helping users verify key assumptions quickly and make better decisions with confidence.
Cash Cows
Tresiba 100 and 200 U basal insulin
Tresiba 100 and 200 U/mL is a mature basal insulin with a broad global footprint, so it fits Novo Nordisk A/S’s Cash Cows bucket. In a low-growth insulin market, demand stays recurring because patients need steady replacement therapy, and the brand still holds meaningful share. That makes cash flow stable, while commercial spend stays lighter than in faster-growing categories.
NovoRapid NovoLog rapid insulin aspart
Novo Nordisk A/S’s NovoRapid NovoLog (insulin aspart) is a mature insulin franchise with long-standing physician trust and broad chronic-use demand. In 2025, Novo Nordisk A/S reported DKK 290.4 billion in revenue, and established insulins like this helped fund growth bets by converting a stable, low-growth base into cash. That steady, repeat prescription stream makes it a clear cash cow in the BCG Matrix.
Norditropin somatropin long-running franchise
Norditropin is a long-running growth hormone franchise with durable demand, and it fits the cash cow role in Novo Nordisk A/S’s BCG matrix. The brand sits in a low-growth market, but Novo Nordisk’s strong position supports steady margins and recurring cash flow. In 2024, Novo Nordisk reported DKK 290.4 billion in sales, and mature brands like Norditropin help fund growth areas while staying cash generative.
NovoSeven 1996 rare bleeding disorders
NovoSeven, launched in 1996, is a mature hemostasis drug with entrenched use in rare bleeding disorders and inhibitor cases. Its niche specialist base and low direct substitution make demand relatively stable, so it fits the Cash Cow role in Novo Nordisk A/S BCG Matrix. In FY2024, Novo Nordisk reported DKK 290.4bn in revenue, and NovoSeven remained a steady legacy contributor.
- Launched in 1996
- Specialist rare-bleeding market
- Low substitution risk
- Stable cash generation
NovoFine NovoTwist pen needles
NovoFine NovoTwist is a Cash Cow because pen needles sit on a huge installed base of Novo Nordisk injectable users. Demand is recurring and sticky, while volume growth is modest, so the line keeps throwing off steady cash rather than fast growth.
- Recurring use from every injection
- Low growth, high repeat demand
- Scale supports lower unit costs
- Margin stays protected by efficiency
Novo Nordisk’s Cash Cows: Steady Repeat Revenue from Mature Brands
Cash Cows in Novo Nordisk A/S are mature, repeat-use lines like Tresiba, NovoRapid, Norditropin, NovoSeven, and NovoFine NovoTwist. They sit in low-growth markets but keep producing steady cash because patients and clinics need them again and again.
| Product | Why it fits |
|---|---|
| Tresiba | Mature basal insulin |
| NovoRapid | Recurring chronic use |
| Norditropin | Stable niche demand |
| NovoSeven | Rare-disease niche |
Preview Before You Purchase
Novo Nordisk A/S Reference Sources
The Novo Nordisk A/S BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages, no watermarks—just the full, ready-to-use report. Once purchased, it’s delivered instantly for download, printing, or presentation. What you see here is what you get.
Dogs
Saxenda 3.0 mg liraglutide 2014
Saxenda 3.0 mg liraglutide, launched in 2014, is an older obesity brand that has lost momentum as Wegovy 2.4 mg semaglutide and newer incretin drugs took demand. In Novo Nordisk A/S’s 2025 obesity portfolio, it sits in a slower-growth lane with weaker strategic pull, so it fits a Dog in the BCG matrix. The once-daily injection now looks like a low-priority asset, with growth and capital better directed to newer brands.
Levemir insulin detemir 2024 exit
Levemir (insulin detemir) is a legacy basal insulin with declining relevance, and Novo Nordisk has already moved away from it in key markets, including the U.S. in 2024. Its growth is weak and its strategic value is low because newer basal insulins and GLP-1 drugs are taking demand. In BCG terms, Levemir fits a Dog: low growth, low share, and little future cash-flow potential.
Fiasp faster aspart 2017
Fiasp, launched in 2017, still has not matched Novo Nordisk A/S core insulin brands like NovoLog/NovoRapid, so its share stays small in a mature, crowded insulin market. In 2025, the category was still led by a few giant injectables, while faster-aspart remained a niche option with limited adoption and weaker pricing power. That profile fits dog territory in the BCG Matrix.
Xultophy IDegLira 2014
Xultophy IDegLira is a mature combo therapy in a slow, crowded diabetes market, and it has not turned into a major growth engine for Novo Nordisk A/S. Its visibility is far below semaglutide-led brands like Ozempic and Wegovy, and its share and growth profile remain weak.
In Novo Nordisk A/S 2025 reporting, Xultophy stayed a small line item versus the company’s far larger GLP-1 franchise, which drove most of the group’s sales growth. That makes Xultophy a clear Dogs case: low growth, limited strategic pull, and low market momentum.
- Low growth, weak share, small sales impact
- Outshined by semaglutide-based brands
- Not a key 2025-2026 growth driver
Mixtard Protaphane Actrapid legacy insulins
Mixtard, Protaphane, and Actrapid are mature human-insulin brands with low strategic value in Novo Nordisk A/S's BCG matrix. They face pricing pressure from newer analog insulins and GLP-1 drugs; by 2025, Novo Nordisk A/S's growth was driven by semaglutide-based products, not these legacy lines. So they fit the dog category: low growth, weak share, limited capital priority.
- Mature, price-sensitive brands
- Loss share to analog insulin
- Outpaced by GLP-1 growth
- Low priority for new investment
Novo Nordisk’s Legacy Brands Fall into the Dog Bucket
In Novo Nordisk A/S 2025, Saxenda, Levemir, Fiasp, Xultophy, Mixtard, Protaphane, and Actrapid sit in the Dog bucket: mature, low-growth, and losing share to Wegovy, Ozempic, and newer insulins. Levemir was exited from the U.S. in 2024, and Saxenda and Xultophy remain small versus the GLP-1 engine. Capital should stay focused on higher-growth brands.
| Brand | Dog signal |
|---|---|
| Saxenda | Older obesity asset |
| Levemir | Legacy, declining |
| Fiasp | Niche share |
| Xultophy | Low momentum |
Question Marks
CagriSema phase 3 obesity pipeline
CagriSema is Novo Nordisk A/S’s high-upside phase 3 obesity asset, aimed at a market where WHO says over 890 million adults live with obesity. The prize is huge, but sales are still unproven because approval, pricing, and uptake are not locked in. That mix of big demand and high execution risk makes it a classic question mark.
Amycretin phase 1 and 2 obesity asset
Amycretin is an early but meaningful obesity bet: Novo Nordisk’s phase 1 data showed double-digit weight loss, but the asset is still too new to size share potential. With obesity drugs already driving Novo Nordisk’s 2024 sales to DKK 290.4 billion, the upside is real, yet phase 2 and later readouts must prove durability and safety. That makes Amycretin a classic high-upside Question Mark.
Awiqli insulin icodec once weekly
Awiqli, the once-weekly insulin icodec, is Novo Nordisk A/S's first basal insulin with weekly dosing, so it fits a Question Mark: high potential, low proven share. Phase 3 ONWARDS data showed non-inferior HbA1c control versus daily basal insulin, but uptake is still early and payer, doctor, and patient response is not yet clear. If physicians value fewer injections, it could scale fast; if not, share stays untested.
Ziltivekimab phase 3 cardiometabolic
Ziltivekimab is in phase 3 for inflammation-linked cardiometabolic disease, a market tied to chronic kidney disease and cardiovascular risk, where CKD affects about 1 in 10 adults worldwide. The science is strong, but Novo Nordisk A/S has not yet proved commercial uptake, pricing power, or label breadth.
That makes it a question mark in the BCG Matrix: high potential, low certainty. Late-stage success and FDA and EMA progress still have to turn phase 3 data into sales, especially in a space where the addressable patient pool is large but outcomes are not yet validated.
- Large unmet need, but unproven revenue
- Phase 3 execution now drives value
- Regulatory approval is still the gate
Mim8 phase 3 hemophilia A
Mim8 is Novo Nordisk A/S's phase 3 hemophilia A pipeline asset, aimed at a rare market where hemophilia A affects about 1 in 5,000 male births. The chance is real, but share is unproven, so it fits BCG question mark territory: high need, high uncertainty, and no clear cash engine yet.
If the phase 3 data and launch land well, Mim8 can move toward star status; if not, it stays a costly bet. In rare-disease drugs, execution matters as much as science, and a small prescriber base can still mean strong value if adoption is fast.
- Phase 3 asset, not yet proven.
- Rare market, but share is unset.
- Success depends on trial and launch.
- High-risk, high-reward question mark.
Novo’s Pipeline: Big Bets, Big Markets, Still Unproven
Question marks in Novo Nordisk A/S are growth bets with huge markets but no proven sales moat yet. CagriSema, Amycretin, Awiqli, Ziltivekimab, and Mim8 all sit in late or early trials, so value depends on 2025-2026 readouts, approval, and launch uptake.
| Asset | Status | Why it is a question mark |
|---|---|---|
| CagriSema | Phase 3 | Big obesity market, unproven sales |
| Amycretin | Phase 1 | Early data, share unknown |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.